- Home
- ANY vs BCAB Comparison
ANY vs BCAB Comparison
Compare ANY & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANY
- BCAB
- Stock Information
- Founded
- ANY N/A
- BCAB 2007
- Country
- ANY United States
- BCAB United States
- Employees
- ANY N/A
- BCAB N/A
- Industry
- ANY Finance: Consumer Services
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- ANY Finance
- BCAB Health Care
- Exchange
- ANY Nasdaq
- BCAB Nasdaq
- Market Cap
- ANY 25.2M
- BCAB 27.0M
- IPO Year
- ANY N/A
- BCAB 2020
- Fundamental
- Price
- ANY $0.55
- BCAB $0.31
- Analyst Decision
- ANY Strong Buy
- BCAB Buy
- Analyst Count
- ANY 1
- BCAB 2
- Target Price
- ANY $3.00
- BCAB $5.00
- AVG Volume (30 Days)
- ANY 315.3K
- BCAB 1.1M
- Earning Date
- ANY 03-21-2025
- BCAB 03-25-2025
- Dividend Yield
- ANY N/A
- BCAB N/A
- EPS Growth
- ANY N/A
- BCAB N/A
- EPS
- ANY N/A
- BCAB N/A
- Revenue
- ANY $21,657,000.00
- BCAB $11,000,000.00
- Revenue This Year
- ANY N/A
- BCAB N/A
- Revenue Next Year
- ANY N/A
- BCAB N/A
- P/E Ratio
- ANY N/A
- BCAB N/A
- Revenue Growth
- ANY 38.44
- BCAB N/A
- 52 Week Low
- ANY $0.53
- BCAB $0.24
- 52 Week High
- ANY $1.90
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- ANY 28.15
- BCAB 32.63
- Support Level
- ANY $0.55
- BCAB $0.24
- Resistance Level
- ANY $0.69
- BCAB $0.36
- Average True Range (ATR)
- ANY 0.06
- BCAB 0.04
- MACD
- ANY 0.00
- BCAB 0.01
- Stochastic Oscillator
- ANY 11.82
- BCAB 29.39
About ANY Sphere 3D Corp.
Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Digital Mining and Service and Product. The Digital Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.